Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors.

Phytic acid (IP-6) is a polyphosphorylated carbohydrate with antitumor activity for many kinds of tumors. In this study, we developed a novel method of loading irinotecan (CPT-11) into liposomes using IP-6, and evaluated its antitumor effect on colon tumors in vivo. Liposomal CPT-11 was prepared by loading CPT-11 to distearoylphosphatidylcholine/cholesterol/methoxy-poly(ethyleneglycol)-distearylphosphatidylethanolamine liposomes prepared in IP-6 solution, CuSO(4) solution and citrate buffer, respectively (IP6-, Cu- and Cit-L). CPT-11 loading efficiency for IP6-L (90-100%) was higher than that for Cit-L (less than 40%), and similar to Cu-L when CPT-11 to total lipid weight ratio was increased from 0.2 to 0.6. Plasma elimination and biodistribution of liposomal CPT-11 and its metabolite SN-38 were measured after intravenous administration. IP6-L following i.v. injection showed 1.3- and 1.7-fold higher plasma area under the curves of CPT-11 and SN-38, respectively, than Cu-L. Finally, therapeutic activity was determined in mouse Colon 26 and human COLO 320DM tumor xenografts in mice. IP6-L significantly exhibited superior anticancer activity to Cu-L and free CPT-11 in Colon 26 tumor. Using IP-6 as a drug-trapping agent in liposome, IP6-L improved CPT-11 pharmacokinetics and increased antitumor activity in colon tumors.

[1]  Anitha Thomas,et al.  Transition Metal-Mediated Liposomal Encapsulation of Irinotecan (CPT-11) Stabilizes the Drug in the Therapeutically Active Lactone Conformation , 2006, Pharmaceutical Research.

[2]  M. Bally,et al.  A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[3]  L. Liu,et al.  Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. , 1989, Cancer research.

[4]  Ivana Vucenik,et al.  Cancer inhibition by inositol hexaphosphate (IP6) and inositol: from laboratory to clinic. , 2003, The Journal of nutrition.

[5]  L. Saltz,et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.

[6]  John W. Park,et al.  Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. , 2006, Cancer research.

[7]  L. Skibsted,et al.  Heterometallic manganese/zinc-phytate complex as a model compound for metal storage in wheat grains. , 2005, Journal of inorganic biochemistry.

[8]  L. Liu,et al.  Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. , 1988, Cancer research.

[9]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[10]  A. Shamsuddin.  Metabolism and cellular functions of IP6: a review. , 1999, Anticancer research.

[11]  Corrie Lynn Messerer,et al.  Liposomal Irinotecan , 2004, Clinical Cancer Research.

[12]  I-Ming Chu,et al.  Effect of composition on the stability of liposomal irinotecan prepared by a pH gradient method. , 2003, Journal of bioscience and bioengineering.

[13]  S. Kawanishi,et al.  Hydroxyl radical and singlet oxygen production and DNA damage induced by carcinogenic metal compounds and hydrogen peroxide , 1989, Biological Trace Element Research.

[14]  F. Crosson,et al.  Acute copper intoxication. Pathophysiology and therapy with a case report. , 1977, American journal of diseases of children.

[15]  F. Roquet,et al.  Preclinical evaluation of CPT-11 and its active metabolite SN-38. , 1996, Seminars in oncology.

[16]  M. Bally,et al.  Copper-topotecan complexation mediates drug accumulation into liposomes. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[17]  G. Giaccone,et al.  CPT‐11 in human colon‐cancer cell lines and xenografts: Characterization of cellular sensitivity determinants , 1997, International journal of cancer.

[18]  Z. Dzierżewicz,et al.  Quantitative Analysis of the Level of P53 and P21 Waf1 Mrna in Human Colon Cancer Ht-29 Cells Treated with Inositol Hexaphosphate , 2006 .

[19]  V. Sakhuja,et al.  Acute copper intoxication. , 1979, The International journal of artificial organs.

[20]  Jing Chen,et al.  Phosphoinositide 3‐kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death , 2008, International journal of cancer.

[21]  Lawrence Mayer,et al.  Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes. , 2007, International journal of pharmaceutics.

[22]  J. Diallo,et al.  An androgen‐independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines , 2006, The Prostate.

[23]  Shamsuddin Am,et al.  Up-regulation of the tumor suppressor gene p53 and WAF1 gene expression by IP6 in HT-29 human colon carcinoma cell line. , 1998 .

[24]  Ivana Vucenik,et al.  Anti-angiogenic activity of inositol hexaphosphate (IP6). , 2004, Carcinogenesis.

[25]  L. Liu,et al.  Topoisomerases: novel therapeutic targets in cancer chemotherapy. , 1988, Biochemical pharmacology.

[26]  M. Bally,et al.  Irinophore C: A Liposome Formulation of Irinotecan with Substantially Improved Therapeutic Efficacy against a Panel of Human Xenograft Tumors , 2008, Clinical Cancer Research.

[27]  A. Shamsuddin,et al.  Inositol Hexaphosphate (IP6) Enhances the Anti-Proliferative Effects of Adriamycin and Tamoxifen in Breast Cancer , 2003, Breast Cancer Research and Treatment.

[28]  Y. Takakura,et al.  Histogram analysis of pharmacokinetic parameters by bootstrap resampling from one-point sampling data in animal experiments. , 2006, Drug metabolism and pharmacokinetics.

[29]  A. Shamsuddin,et al.  Up-regulation of the tumor suppressor gene p53 and WAF1 gene expression by IP6 in HT-29 human colon carcinoma cell line. , 1998, Anticancer research.

[30]  A. Shamsuddin,et al.  G0/G1 arrest and S phase inhibition of human cancer cell lines by inositol hexaphosphate (IP6). , 2001, Anticancer research.

[31]  Y. Maitani,et al.  Cationic liposome (DC-Chol/DOPE=1:2) and a modified ethanol injection method to prepare liposomes, increased gene expression. , 2007, International journal of pharmaceutics.

[32]  R. Agarwal,et al.  In Vivo Suppression of Hormone-Refractory Prostate Cancer Growth by Inositol Hexaphosphate , 2004, Clinical Cancer Research.

[33]  Kensuke Matsumoto,et al.  Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice , 2004, Cancer Chemotherapy and Pharmacology.

[34]  H. Kuga,et al.  Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.

[35]  L. Saltz.  The role of irinotecan in colorectal cancer , 1999, Current oncology reports.